Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing
Patent
1996-03-15
1998-11-17
Chambers, PHD., Jasemine C.
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
424 932, 435375, A61K 4800, C12N 500
Patent
active
058372334
ABSTRACT:
A method is provided for treatment of a mammalian patient having a tumor by administering to the patient allogenic donor lymphocytes that have been co-cultured in the presence of the patient-derived lymphocytes under conditions sufficient to alloactivate the donor lymphocytes. It is preferred that the donor lymphocytes be introduced intralesionally. This method is preferred for treatment of glioblastoma in humans.
REFERENCES:
patent: 4038145 (1977-07-01), Devlin
patent: 4677056 (1987-06-01), Dupont et al.
patent: 5057423 (1991-10-01), Hiserodt et al.
patent: 5308626 (1994-05-01), Landucci et al.
patent: 5382427 (1995-01-01), Plunkett et al.
patent: 5484596 (1996-01-01), Hanna, Jr. et al.
Bellgrau, "Induction of cytotoxic T cell precursors in vivo" J. Exp. Med. (1983) 157:1505-1515.
Chang et al., "Phase I clinical trial of allogeneic lymphocyte culture (cytoimplant) delivered by endoscopic ultrasound (EUS)-guided fine needle injection (FNI) in patients with advanced pancreatic carcinoma" Castroenterology (1997) 112(4):A546.
Fleshner et al., "Potential of allogneic Tumoricidal cytotoxic T lymphocytes in brain tumor adoptive immunotherapy" J. Cell. Biochem. (1990) Suppl. 0 (14 part B):95 (abstract CE 407).
Kruse et al., "Cellular therapy of brain tumors: Clinical trials" Advances in Neuro-Oncology II, Kornblith et al., eds., Futura Publishing Company, Inc., Armonk, NY, (1997) Chapter 22, pp. 487-504.
Kruse et al., "Development of human allogeneic CTL in an artificial system for intercavitary treatment of malignant glioma" Proc. Amer. Assoc. Cancer Res. (1995) 36:474 (abstract No. 2822).
Kruse et al., "Immune therapy of recurrent mailgnant gliomas: Intracavitary allogeneic cytotoxic T lymphocytes and human recombinant interleukin-2" FASEB J. (1996) 10(6):A1413 (abstract 2387).
Kruse et al., "Migration of activated lymphocytes when adoptively transferred into cannulated rat brain" J. Neuroimmunol. (1994) 55:11-21.
Kruse et al., "Artificial-capillary-system development of human alloreactive cytotoxic T-lymphocytes that lyse brain tumour" Biotechnol. Appl. Biochem. (1997) 25: (pre-publication copy) 9 pages total.
Kruse et al., "Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: Allogeneic cytotoxic T lymphocytes prevent tumor take," Proc. Natl. Acad. Sci., vol. 87: 9577-9582, Dec. 1990.
Reed et al., "Allogeneic tumor-specific cytotoxic T lymphocytes" Cancer Immunol. Immunother. (1992) 34:349-354.
Schiltz et al., "Movement of allogeneic cytotoxic T lymphocytes (aCTL) infused into the parietal region of 9L gliosarcoma bearing brain" Proc. Assoc. Cancer Res. (1995) 36:458 (Abstract No. 2727).
Schlitz et al., "Treatment of 9L gliosarcoma with interferon-gamma enhances its cytolysis by alloreactive cytotoxic T lymphocytes in vitro" FASEB J. (1995)9(4):A1044 (abstract 6052).
Streilein et al., "Unraveling immune response" Science (1995)270:1158-1159.
Albright et al., "Immunogenetic control of brain tumor growth in rats" Cancer Res. (1977) 37:2512-2522.
Barba et al., "Intratumoral LAK cell and interleukin-2 therapy of human gliomas" J. Neurosurg, (1989) 70:175-182.
Cavallo et al., "Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene" J. Immunol. (1992) 149(11):3627-3635.
Colombo et al., Tumor cells engineered to produce cytokines of cofactors as cellular vaccines: Do animal studies really support clinical trials? Cancer Immunol. Immunother. (1995) 41:265-270.
Finke et al., "Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltating lymphocytes in human renal cell carcinoma" Cancer Res. (1990) 50:2363-2370.
Hayes et al., "Recombinant interleukin-2-related intracerebral toxicity and LAK/rIL-2 therapy for brain tumors" Lymphokine Res. (1988) 7(3):337.
Jeffes et al., "Therapy of recurrent high grade gliomas with surgery, autologous mitogen-activated IL-2-stimulated (MAK) killer lymphocytes, and rIL-2: II. Correlation of survival with MAK cell tumor necrosis factor production in vitro" Lymphokine Cytokine Res. (1991) 10(2):89-94.
Kondo et al., "Rationale for a novel immunotherapy of cancer with allogeneic lymphocyte infusion" Med. Hypotheses (1984) 15:241-277.
Kruse et al., "Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma" J. Neuro-Oncol. (1993) 15:97-112.
Kruse et al., "Intracranial administrations of single or multiple source allogeneic cytotoxic T lymphocytes: chronic therapy for primary brain tumors" J. Neuro-Oncol. (1994) 19:161-168.
Leshem et al., "In vitro elicitation of cytotoxic response against a nonimmunogenic murine tumor be allosensitization" Cancer Immunol. Immunother. (1984) 17:117-123.
Merchant et al., "Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2" Cancer (1988) 62:665-671.
Merchant et al., "Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical investigations" J. Neuro-Oncol. (1990) 8:173-188.
Mitchell et al., "Active specific immunotherapy of melanoma with allogeneic cell lysates. Rational, results, and possible mechanisms of action" Ann. N.Y. Acad. Sci. (1993) 690:153-166.
Naganuma et al., "Complete remission of recurrent glioblastoma multiforme following local infusions of lymphokine activated killer cells. Case report" Acta. Neurochir. (1989) 99:157-160.
Rosenburg et al., "A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high doses interleukin-2 alone" New England Journal of Medicine(1987) 316(15):889-897.
Strausser et al., "Lysis of human solid tumors by autologous cells sensitized in vitro to alloantigens" J. Immunol. (1981) 127(1):266-271.
Topalian et al., "Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: A pilot study" J. Clin. Oncol. (1988) 6(5):839-853.
Yoshida et al., "Local administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with malignant brain tumors" Cancer Res. (1988) 48:5011-5016.
Zarling et al., "Generation of cytotoxic T lymphocytes to autologous human leukemia cells by sensitization to pooled allogeneic normal cells" Nature (1978) 274:269-271.
Fletcher, et al., Recent Advances in the Understanding of the Biochemistry and Clinical Pharmacology of Interleukin-2, Lymphokine Research, 1987, vol. 6, No. 1, pp. 45-57.
Carson, et al., Rat Mitogen-Stimulated Lymphokine-Activated T Killer Cells: Production and Effects on C.sub.6 Glioma Cells in Vitro and In Vivo in the Brain of Wistar Rats, Journal of Immunotherapy, 1991, vol. 10, No. 2, pp. 131-140.
Ammirati et al., "Reoperation in the treatment of recurrent intracranial malignant gliomas." Neurosurgery (1987) 21:607-614.
Harsh et al., "Reoperation for recurrent glioblastoma and anaplastic astrocytoma." Neurosurgery (1987) 21:615-621.
Redd et al., "Allogeneic tumor-specific cytotoxic T lymphocytes" Cancer Immunol. Immunother. (1992) 34:349-354.
Schiltz et al., "Treatment of 9L gliosarcoma with interferon-gamma enhances its cytolysis by alloreactive cytotoxic T lymphocytes in vitro" FASEB J. (1995) 9(4):A1044 (Abstract 6052).
Wekerle., "Lymphocyte traffic to the brain" pp. 67-85 in The Blood-Brain Barrier, W.M. Pardridge, ed., Raven Press Ltd, NY (1993).
Zeltzer et al., "Brain tumor vaccines and artificial lymph nodes in brain tumors--fantasy or reality?" Med. Ped. Oncol. (1995) 25:277.
Appendix A: Curriculum vitae of Gale A. Granger.
Appendix B (item 1): E.W.B. Jeffes et al. Therapy of recurrent high grate gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) lymphocytes . . . J. Neuro-Oncol. 15:141-155, 1993.
Appendix B (item 2): R.S. Yamamoto et al. Basical and clinical studies with intratumor immonotherapy of gliomas with alloimmune lymphoid cells. Poster presentation, American Association
Chambers, PHD. Jasemine C.
Hauda Karen M.
University of California
LandOfFree
Method for treating tumors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating tumors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating tumors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-881308